How unbiased is non-targeted metabolomics and is targeted pathway screening the solution?

Current Pharmaceutical Biotechnology

Volumn 12, Issue 7, 2011, Pages 1053-1066

  Christians, Uwe ^a   Klawitter, Jelena ^a   Hornberger, Andrea ^a   Klawitter, Jost ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

Chemometrics; Metabolic pathways; Metabolomics; Qualification; Quantitation; Targeted non targeted; Validation; Verification

Indexed keywords

2 BROMOETHYLAMINE; AMINOPHENOL; CISPLATIN; CYCLOSPORIN; DEXTRO SERINE; DOXORUBICIN; GENTAMICIN; HEXACHLOROBUTADIENE; MERCURIC CHLORIDE; MOLECULAR MARKER; OCHRATOXIN; PUROMYCIN; SODIUM CHROMATE; THIOACETAMIDE; URANYL NITRATE;

ARTICLE; ATMOSPHERIC PRESSURE; BIOSTATISTICS; CHEMOMETRIC ANALYSIS; GAS CHROMATOGRAPHY; HUMAN; INFORMATION PROCESSING; LIQUID CHROMATOGRAPHY; METABOLISM; METABOLOME; METABOLOMICS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SCREENING; SENSITIVITY ANALYSIS;

ANIMALS; ARTIFACTS; GENE EXPRESSION PROFILING; HUMANS; MASS SPECTROMETRY; METABOLOMICS; PROTEOME; SIGNAL TRANSDUCTION;

EID: 79959326938     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795909078     Document Type: Article

References (79)

1. Nicholson, J.K.; Lindon, J.C. Metabonomics. Nature, 2008, 455, 1054-1056.
2. Holmes, E.; Wilson, I.D.; Nicholson, J.K. Metabolic phenotyping in health and disease. Cell, 2008, 134, 714-717.
3. Nicholson, J.K. Global systems biology, personalized medicine and olecular epidemiology. Mol. Syst. Biol., 2006, 2, 52.
4. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69, 89-95.
5. Koop, R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov. Today, 2005, 10, 781-788.
6. Xu, E.Y.; Schaefer, W.H.; Xu, Q. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Cur. Opin. Drug Discov. Dev., 2009, 12, 40-52.
7. Nicholson, J.K.; Wilson, I.D. Understanding global systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov., 2003, 2, 668-676.
8. Nobeli, I.; Thornton, J.M. A bioinformatician's view of the metabolome. Bioassays, 2006, 28, 534-545.
9. Coen, M.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem. Res. Toxicol., 2008, 21, 9-27.
10. Oldiges, M.; Lütz, S.; Pflug, S.; Schroer, K.; Stein, N.; Wiendahl, C. Metabolomics: current state and evolving methodologies and tools. Appl. Microbiol. Biotechnol., 2007, 76, 495-511.
11. Xia, J.; Bjorndahl, T.C.; Tang, P.; Wishart, D.S. MetaboMiner--semi-automated identification of metabolites from 2D NMR spectra of complex biofluids. BMC Bioinformatics, 2008, 28, 507.
12. Almstetter, M.F.; Appel, I.J.; Gruber, M.A.; Lottaz, C.; Timischl, B.; Spang, R.; Dettmer, K.; Oefner, P.J. Integrative normalization and comparative analysis for metabolic fingerprinting by comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry. Anal. Chem., 2009, 81, 5731-5739.
13. Nicholson JK; Connelly J; Lindon JC; Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov., 2002, 1, 153-161.
14. Matsuda, F.; Shinbo, Y.; Oikawa, A.; Hirai, M.Y.; Fiehn, O.; Ka-naya, S.; Saito, K. Assessment of metabolome annotation quality: a method for evaluating the false discovery rate of elemental composition searches. PLoS One, 2009, 16, e7490.
15. Christians, U.; Albuisson, J.; Klawitter, J.; Klawitter, J. The Role of Metabolomics in the Study of Kidney Diseases and in the Development of Diagnostic Tools. Biomarkers of Kidney Disease. Edel-stein CL Eds. San Diego: Elsevier, 2011.
16. Klawitter, J.; Haschke, M.; Kahle, C.; Dingmann, C.; Klawitter, J.; Leibfritz, D.; Christians, U. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br. J. Clin. Pharmacol., 2010, 70, 241-251.
17. Dettmer, K.; Aronov, P.A.; Hammock, B.D. Mass spectrometry-based metabolomics. Mass. Spectrom. Rev., 2007, 26, 51-78.
18. Gowda, G.A.; Zhang, S.; Gu, H.; Asiago, V.; Shanaiah, N.; Raftery, D. Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn., 2008, 8, 617-633.
19. Want, E.J.; Nordström, A.; Morita, H.; Siuzdak, G. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J. Proteome Res., 2007, 6, 459-468.
20. Khoo, S.H.; Al-Rubeai, M. Metabolomics as a complementary tool in cell culture, Biotechnol. Appl. Biochem., 2007, 47(Pt 2), 71-84.
21. Fiehn, O.; Kopka, J.; Dörmann, P.; Altmann, T.; Trethewey, R.N.; Willmitzer, L. Metabolite profiling for plant functional genomics. Nat. Biotechnol., 2000, 18, 1157-1161.
22. Schnackenberg, L.K.; Beger, R.D. Monitoring the health to disease continuum with global metabolic profiling and systems biology. Pharmacogenomics, 2006, 7, 1077-1086.
23. Pasikanti, K.K.; Ho, P.C.; Chan, E.C. Gas chromatography/ mass spectrometry in metabolic profiling of biological fluids. J. Chroma-togr. B. Analyt. Technol. Biomed. Life Sci., 2008, 871, 202-211.
24. Leimer, K.R.; Rice, R.H.; Gehrke, C.W. Complete mass spectra of N-trifluoroacetyl-n-butyl esters of amino acids. J. Chromatogr., 1977, 141, 121-144.
25. Reo, N.V. NMR-based metabolomics. Drug Chem. Toxicol., 2002, 25, 375-382.
26. Pan, Z.; Raftery, D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal. Chem., 2007, 387, 525-527.
27. 1H-NMR-based metabolic signatures of mild and severe ische-mia/reperfusion injury in rat kidney transplants. Kidney. Int., 2005, 67, 1142-1151.
28. Xia, J.; Bjorndahl, T.C.; Tang, P.; Wishart, D.S. MetaboMiner--semi-automated identification of metabolites from 2D NMR spectra of complex biofluids. BMC Bioinformatics, 2008, 28, 507.
29. Want, E.J.; O'Maille, G.; Smith, C.A.; Brandon, T.R.; Uritboonthai, W.; Qin, C.; Trauger, S.A.; Siuzdak, G. Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem., 2006, 78, 743-752.
30. Nordström, A.; Want, E.; Northen, T.; Lehtiö, J.; Siuzdak, G. Multiple ionization mass spectrometry strategy used to reveal the complexity of metabolomics. Anal. Chem., 2008, 80, 421-429.
31. Annesley, T.M. Ion suppression in mass spectrometry. Clin. Chem., 2007, 49, 1041-1044.
32. Dunn, W.B.; Bailey, N.J.; Johnson, H.E. Measuring the me-tabolome: current analytical technologies. Analyst, 2005, 130, 606-625.
33. Boernsen, K.O.; Gatzek, S.; Imbert, G. Controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasma. Anal. Chem., 2005, 77, 7255-7264.
34. Deming, S.N. Chemometrics: an overview. Clin. Chem., 1986, 32, 1702-1706.
35. Beger, R.D.; Sun, J.; Schnackenberg, L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxic-ity and nephrotoxicity. Toxicol. Appl. Pharmacol., 2010, 243, 154-166.
36. Wishart, D.S. Computational approaches to metabolomics. Methods Mol. Biol., 2010, 593, 283-313.
37. Oresic, M.; Vidal-Puig, A; Hänninen, V. Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev. Mol. Diagn., 2006, 6, 575-585.
38. Issaq, H.J.; Van, Q.N.; Waybright, T.J.; Muschik, G.M.; Veenstra, T.D. Analytical and statistical approaches to metabolomics research, J. Sep. Sci., 2009, 32, 2183-2199.
39. Wishart, D.S. Current progress in computational metabolomics. Brief Bioinform., 2007, 8, 279-293.
40. Kaddurah-Daouk, R.; Kristal, B.S.; Weinshilboum, R.M. Me-tabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 653-683.
41. Baumgartner, W.A. Jr.; Cohen, K.B.; Fox, L.M.; Acquaah-Mensah, G.; Hunter, L. Manual curation is not sufficient for annotation of genomic databases. Bioinformatics, 2007, 23, i41-i48.
42. Wheelock, C.E.; Wheelock, A.M.; Kawashima, S.; Diez, D.; Kane-hisa, M.; van Erk, M.; Kleemann, R.; Haeggström, J.Z.; Goto, S. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol. Biosyst., 2009, 5, 588-602.
43. Wishart, D.S. Introduction to cheminformatics. Curr. Protoc. Bio-informatics, 2007, Chapter 14, Unit 14.1.
44. Materi, W.; Wishart, D.S. Computational systems biology in drug discovery and development: methods and applications. Drug Dis-cov. Today, 2007, 12, 295-303.
45. Leach, S.M.; Tipney, H.; Feng, W.; Baumgartner, W.A.; Kasliwal, P.; Schuyler, R.P.; Williams, T.; Spritz, R.A.; Hunter, L. Biomedi-cal discovery acceleration, with applications to craniofacial development. PLoS Comput. Biol., 2009, 5, e1000215.
46. Wishart, D.S.; Knox, C.; Guo, A.C.; Eisner, R.; Young, N.; Gautam, B.; Hau, D.D.; Psychogios, N.; Dong, E.; Bouatra, S.; Mandal, R.; Sinelnikov, I.; Xia, J.; Jia, L.; Cruz, J.A.; Lim, E.; Sob-sey, C.A.; Shrivastava, S., Huang, P., Liu, P., Fang, L., Peng, J., Fradette, R.; Cheng, D.; Tzur, D.; Clements, M.; Lewis, A.; De Souza, A.; Zuniga, A.; Dawe, M.; Xiong, Y.; Clive, D.; Greiner, R.; Nazyrova, A.; Shaykhutdinov, R.; Li, L.; Vogel, H.J.; Forsythe, I. HMDB: a knowledgebase for the human metabolome. Nucl. Acids Res., 2009, 37 (Database issue), D603-D610.
47. Müller, P.Y.; Dieterle, F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin. Drug Metab. Toxicol., 2009, 5, 1023-1038.
48. Lee, J.W.; Figeys, D.; Vasilescu, J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv. Cancer Res., 2007, 96, 269-298.
49. Burckart, G.J.; Amur, S.; Goodsaid, F.M.; Lesko, L.J.; Frueh, F.W.; Huang, S.M.; Cavaille-Coll, M.W. Qualification of biomarkers for drug development in organ transplantation. Am. J. Transplant., 2008, 8, 267-270.
50. Wagner, J.A.; Williams, S.A.; Webster, C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther., 2007, 81, 104-107.
51. Lesko, L.J.; Atkinson, A.J. Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 347-366.
52. Goodsaid FM; Frueh FW; Mattes W. Strategic paths for biomarker qualification. Toxicology, 2008, 245, 219-223.
53. Goodsaid, F.; Frueh, F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J., 2007, 23, E105-E108.
54. Goodsaid, F.; Frueh, F. Implementing the US FDA guidance on pharmacogenomic data submissions. Environ. Mol. Mutagen., 2007, 48, 354-358.
55. Goodsaid, F.; Frueh, F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics, 2006, 7, 773-782.
56. Rifai, N.; Gillette, M.A.; Carr, S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol., 2006, 24, 971-983.
57. Wishart, D.S. Metabolomics: the principles and potential applications to transplantation. Am. J. Transplant., 2005, 5, 2814-2820.
58. Griffiths, W.J.; Wang, Y. Mass spectrometry: from proteomics to metabolomics and lipidomics, Chem. Soc. Rev., 2009, 38, 1882-1896.
59. Pasikanti, K.K.; Ho, P.C.; Chan, E.C. Gas chromatography/ mass spectrometry in metabolic profiling of biological fluids. J. Chroma-togr. B. Analyt. Technol. Biomed. Life Sci., 2008, 871, 202-211.
60. Shockcor JP; Holmes E. Metabonomic applications in toxicity screening and disease diagnostics. Cur. Top. Med. Chem., 2002, 2, 35-51.
61. 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed., 1998, 11, 235-244.
62. Williams, R.E.; Major, H.; Lock, E.A.; Lenz, E.M.; Wilson, I.D. D-serine nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach. Toxicology, 2005, 207, 179-209.
63. Sieber, M.; Hoffmann, D.; Adler, M.; Vaidya, V.S.; Clement, M.; Bonventre, J.V.; Zidek, N.; Rached, E.; Amberg, A.; Callanan, J.J.; Dekant, W.; Mally, A. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gen-tamycin nephrotoxicity. Toxicol. Sci., 2009, 109, 336-349.
64. Holmes, E.; Bonner, F.W.; Sweatman, B.C.; Lindon, J.C.; Beddell, C.R.; Rahr, E.; Nicholson, J.K. Nuclear magnetic resonance spec-troscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephro-toxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine. Mol. Pharmacol., 1992, 42, 922-930.
65. Lenz, E.M.; Bright, J.; Knight, R.; Wilson, I.D.; Major, H. A me-tabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H-NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst, 2004, 129, 535-541.
66. Nicholson, J.K.; Timbrell, J.A.; Sadler, P.J. Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxic-ity in rats. Mol. Pharmacol., 1985, 27, 644-651.
67. Anthony, M.L.; Gartland, K.P.; Beddell, C.R.; Lindon, J.C.; Nicholson, J.K. Studies of the biochemical toxicology of uranyl nitrate in the rat. Arch. Toxicol., 1994, 68, 43-53.
68. Klawitter, J.; Bendrick-Peart, J.; Rudolph, B.; Beckey, V.; Klawit-ter, J.; Haschke, M.; Rivard, C.; Chan, L.; Leibfritz, D.; Christians, U.; Schmitz, V. Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem. Res. Toxicol., 2009, 22, 118-128.
69. Sieber, M.; Wagner, S.; Rached, E.; Amberg, A.; Mally, A.; Dekant, W. Metabonomic study of ochratoxin A toxicity in rats after repeat administration: phenotypic anchoring enhances the ability for biomarker discovery. Chem. Res. Toxicol., 2009, 22, 1221-1231.
70. Portilla, D.; Li, S.; Nagothu, K.K.; Megyesi, J.; Kaissling, B.; Schnackenberg, L.; Safirstein, R.L.; Beger, R.D. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int., 2006, 69, 2194-2204.
71. 1H NMR spec-troscopy, HPLC-TOF/MS and chemometrics. J Pharm. Biomed. Anal., 2004, 35, 599-608.
72. 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamycin-induced neph-rotoxicity in the rat. Biomarkers, 2005, 10, 173-187.
73. 1H-NMR spec-troscopy. J. Toxicol. Environ. Health A., 2009, 72, 374-384.
74. 2H NMR spectroscopic studies on the metabolism and biochemical effects of 2-bromoethanamine in the rat. Biochem. Pharmacol., 1995, 49, 1349-1359.
75. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine. (2001) Guidance for the Industry. Bioanalytical Method Validation. Version May 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegula toryInformation/Guidances/UCM070107.pdf [last accessed 29 August 2010]
76. Clinical Laboratory and Standard Institute, www.clsi.org [last accessed 29 August 2010]
77. European Agency for the Evaluation of Medicinal Products ICH topic Q2 (R1). Validation of analytical procedures: text and methodology. Note for guidance on analytical procedures: Text and methodology. CPMP ICH/381/95. 1995. http://www.ema.euro-pa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf [last accessed 29 August 2010)
78. Klawitter, J.; Schmitz, V.; Klawitter, J.; Leibfritz, D.; Christians, U. Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization-MS. Anal. Biochem., 2007, 365, 230-239.
79. Lee, B.T.; Liew, L.; Lim, J.; Tan, J.K.; Lee, T.C.; Veladandi, P.S.; Lim, Y.P.; Han, H.; Rajagopal, G.; Anderson, N.L. Candidate List of yoUr Biomarker (CLUB): A web-based platform to aid cancer biomarker research. Biomark. Insights, 2008, 3, 65-71.